VcMMAE
CAS No. : 646502-53-6
(Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin)
| Size | Price | Stock |
|---|---|---|
| 100mg | $319 | In-stock |
| 250mg | $468 | In-stock |
| 1g | $1402 | In-stock |
| 5 g | Get quote | |
| 10 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15575 |
| M.Wt: | 1316.63 |
| Formula: | C68H105N11O15 |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 54 mg/mL;Ethanol : 50 mg/mL (ultrasonic);H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) |
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). In Vitro: Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2]. In Vivo: Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- VcMMAE
- Cat. No.:
- HY-15575
- Quantity:
Your information is safe with us.